We bring foreign life science companies into the American market.
Julien Willard, MD MPH
Founder and CEO
I spent ten years in international diplomacy, brokering partnerships between life science companies across borders. The pattern was consistent: foreign companies that tried to enter the United States failed more often than they succeeded.
The first barrier is cultural. American business moves fast, favors direct communication, and closes on value. Companies from Japan, Korea, and the broader Asia-Pacific — where trust-building precedes any deal — find this disorienting. Most appoint a home-country executive to lead US operations. That approach rarely works. Entering the American market requires American incorporation, American fundraising, and an American commercial strategy.
The second barrier is risk. American business culture rewards aggressive capital deployment. Most foreign markets reward capital preservation. That mismatch, compounded by FDA regulation and a fragmented payer landscape, stops promising drugs, devices, and diagnostics from reaching American patients.
I founded Arcstone in 2018, immediately after wrapping up my diplomatic service. My background — a medical degree, a master's in health economics, and a cross-border network built deal by deal — is the firm's foundation. The job is straightforward: take a foreign life science company with a viable product and get it into the American market.
What we believe.
Every dollar is accountable.
Foreign companies enter the United States with currencies weaker than the dollar. We treat their capital with the discipline that exchange rate demands.
We do the work, not just the strategy presentation.
Strategy presentations do not get products approved or commercialized. We work inside client operations — from entity formation to FDA submissions to commercial launch.
Good medicine should not stop at borders.
Effective drugs, devices, and diagnostics developed outside the United States deserve access to the world’s largest market. That is what we exist to do.
The operating model.
Flat retainers, not hourly billing
Fees are tied to milestones. Clients know the cost before work begins.
AI tools, human expertise
AI produces first drafts — regulatory submissions, market analyses, competitive assessments. Regulatory consultants and subject matter experts take every deliverable to the finish line. A five-person Arcstone team produces the output of 20 at a traditional consultancy.